Aclarion (ACON) Registration Filing summary

Company overview and business model

• Healthcare technology company leveraging Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments for low back and neck pain, a $134.5B U.S. market.

• Employs AI for quality control and aspires to use AI/machine learning for associating MRS data with clinical outcomes and expanding into other diagnostic areas.

• Focuses initially on improving surgical outcomes for lumbar spine pain, with plans to expand to conservative therapies and other anatomical regions.

• Holds a portfolio of 22 U.S. patents, 17 foreign patents, and exclusive licenses from UCSF.

• Clinical studies show improved surgical outcomes when using the technology to identify pain-generating discs.

Financial performance and metrics

• Qualifies as an emerging growth company under the JOBS Act, with less than $1.235 billion in revenue in the last fiscal year.

• Limited sales to date, with ongoing investment in research and development.

• Audited financial statements for 2023 and 2022 include going concern explanatory paragraphs from independent auditors.

Use of proceeds and capital allocation

• Net proceeds intended for market development, clinical evidence, product development, quality, general administration, debt retirement, and other corporate purposes.

• Additional details on use of proceeds to be provided in prospectus supplements for specific offerings.